Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.59 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | DDX3X | O00571 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211383 | 0.81 | NOTUM (0.68) | RXRAGRIN1GRIN2B | |
| SCHEMBL16785617 | 0.81 | NOTUM (0.66) | RXRAGRIN1GRIN2B | |
| SCHEMBL21974270 | 0.79 | RXRA (0.68) | RXRAGRIN1GRIN2BDDX3X | |
| SCHEMBL16271203 | 0.78 | MIF (0.71) | MIFDDX3X | |
| Bromide SCHEMBL1886330 | 0.78 | MIF (0.71) | MIFDDX3X | |
| Bromide SCHEMBL1880908 | 0.77 | MIF (0.69) | MIFDDX3X | |
| Bromide SCHEMBL1890839 | 0.77 | MIF (0.69) | MIFDDX3X | |
| Bromide SCHEMBL1880796 | 0.77 | MIF (0.69) | MIFDDX3X | |
| Bromide SCHEMBL1883955 | 0.77 | MIF (0.69) | MIFDDX3X | |
| SCHEMBL14323567 | 0.75 | HDAC8 (0.59) | RXRAGRIN1GRIN2BDDX3X |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-03-09 | — | — | US | disclosed |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | RXRA 3130/4885GRIN1 3494/4885GRIN2B 3787/4885 |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | DDX3X, DDX39B, DDX1 | RXRA 3130/4885GRIN1 3494/4885GRIN2B 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.